Covaxin is authorized in 14 countries and by the World Health Organization, but the U.S. is not one of them. The U.S. FDA put a clinical hold on a phase 2/3 trial of the shot in April, but removed it in May.
One of the key benefits of Covaxin is that unlike mRNA vaccines, it does not require freezing cold storage.
However, given that Pfizer (PFE)/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX) are all developing Omicron-targeted vaccines, even if Covaxin is authorized, it would face stiff competition.